Jazz Pharmaceuticals (JAZZ) Tops Q4 EPS by 14c
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $258.07 -0.83%
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Financial Fact:
Selling, general and administrative: 124.37M
Today's EPS Names:
EGRX, VAXX, AFIB, More
Join SI Premium – FREE
Jazz Pharmaceuticals (NASDAQ: JAZZ) reported Q4 EPS of $2.44, $0.14 better than the analyst estimate of $2.30. Revenue for the quarter came in at $328.1 million versus the consensus estimate of $319.74 million.
For earnings history and earnings-related data on Jazz Pharmaceuticals (JAZZ) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $281 at Truist Securities
- Meta to pay $18 billion over 10 years for youth online safety initiatives.
- LightInTheBox Holding (LITB) Reports Q2 EPS of $0.01
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
